Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17 CAR T cell therapy that is in Phase I/II multi-centre clinical trials for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a Chlorotoxin CAR T cell therapy, which is in phase Ia/IIb clinical trials for patients with recurrent or progressive Glioblastoma, as well as in preclinical trials for MMP2 expressing solid tumors. It also develops CHM CORE-NK that is in phase Ia/IIb clinical trials for acute myeloid leukaemia/colorectal cancer and acute myeloid cancer, as well as in preclinical trials for blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.